Gemcitabine Intravesical System in Practice: Operational Considerations for Oncology Pharmacists

Gemcitabine intravesical system (Inlexzo; Johnson & Johnson) sits at the intersection of oncology pharmacy and urology in a way that few approved therapies do. It is simultaneously an FDA-approved antineoplastic drug and a device inserted by a urologist—a combination that creates real operational questions about who owns what in the care pathway.